TY - CHAP
T1 - Neuropeptides in drug research
AU - Poyner, David
AU - Cox, Helen
AU - Bushfield, Mark
AU - Treherne, J. Mark
AU - Demetrikopoulos, Melissa K.
PY - 2000
Y1 - 2000
N2 - Neuropeptides have been a subject of considerable interest in the pharmaceutical industry over the last 20 years or more. Many drug discovery teams have contributed to our understanding of neuropeptide biology but no significant drugs that act selectively upon neuropeptide receptors have yet emerged from the clinic. There are, however, a plethora of clinically useful drugs that act at other classes of neurotransmitter and neuromodulator receptors, many of them discovered over the last 20 years. Nevertheless, we think that the future for the discovery of novel drugs acting at neuropeptide receptors looks bright for two reasons: (1) there has been a substantial increase in our understanding of the function of neuropeptides; and (2) high-throughput screening (HTS) against neuropeptide receptors has now begun to yield many interesting drug-like molecules, rather than peptides, that have the potential to become clinically useful drugs.
AB - Neuropeptides have been a subject of considerable interest in the pharmaceutical industry over the last 20 years or more. Many drug discovery teams have contributed to our understanding of neuropeptide biology but no significant drugs that act selectively upon neuropeptide receptors have yet emerged from the clinic. There are, however, a plethora of clinically useful drugs that act at other classes of neurotransmitter and neuromodulator receptors, many of them discovered over the last 20 years. Nevertheless, we think that the future for the discovery of novel drugs acting at neuropeptide receptors looks bright for two reasons: (1) there has been a substantial increase in our understanding of the function of neuropeptides; and (2) high-throughput screening (HTS) against neuropeptide receptors has now begun to yield many interesting drug-like molecules, rather than peptides, that have the potential to become clinically useful drugs.
KW - Calcitonin gene-related peptide (CGRP)
KW - Central nervous system
KW - Cholecystokinin
KW - Galanin
KW - Neuropeptide Y
KW - Neuropeptides
KW - Opioid peptides
KW - Peripheral nervous system
KW - Substance P
UR - http://www.scopus.com/inward/record.url?scp=0034108393&partnerID=8YFLogxK
UR - https://link.springer.com/book/10.1007/978-3-0348-8391-7
U2 - 10.1007/978-3-0348-8391-7_4
DO - 10.1007/978-3-0348-8391-7_4
M3 - Chapter (peer-reviewed)
C2 - 10857387
AN - SCOPUS:0034108393
SN - 978-3-7643-6113-6
SN - 978-3-0348-9546-0
VL - 54
T3 - Progress in Drug Research
SP - 121
EP - 149
BT - Progress in Drug Research
A2 - Junker, Ernst
PB - Springer
CY - Cham, Switzerland
ER -